Cancer Research

{
  "result": " This tick’s most exciting development was a strategic insight forged from an initial null: after scanning 157 biological entities and finding zero hardened causal relations, the swarm discovered exactly where to look next. It abandoned broad scraping and locked onto two high-leverage axes in colorectal cancer (CRC)—the *LDLR* cholesterol receptor at 19p13.11 and the *PTGS2* inflammation hub at 1q31.1—where tissue-specific gene regulation, multi-ancestry disease genetics, and CRISPR co-dependency data can be triangulated. Critically, the AI is now treating CRC not as a single disease, but as two distinct molecular subtypes: microsatellite stable (MSS) tumors, which are typically chromosomally unstable and often carry *APC* mutations, and microsatellite unstable (MSI) tumors, which are hypermutated and clinically distinct. This pivot from noisy breadth to subtype-stratified depth suggests that the fastest path to a hardened causal edge runs through these two genes.\n\nTo test this, the swarm executed three integrated analyses. For *LDLR*, it investigated whether the same genetic variants that control cholesterol metabolism in liver and colon tissue also influence CRC risk across populations, and whether a person’s inherited cholesterol and body-mass profiles interact to push cancer risk specifically toward the MSS or MSI subtype in both European and East Asian ancestries. For *PTGS2*—an enzyme with a known role in MSS tumorigenesis—the AI derived instruments from normal sigmoid colon and from single-cell atlases of the tumor microenvironment, including cancer-associated fibroblasts and macrophages, to test whether stromal infiltration (the structural and immune scaffolding around a tumor) changes *PTGS2*’s causal impact by subtype. In parallel, the swarm mined DepMap CRISPR knockout screens, hunting for synthetic lethality: a selective vulnerability where disabling *PTGS2* kills *APC*-mutant, chromosomally unstable cells but spares MSI cells.\n\nNo new causal edges were validated this tick—an honest null that reflects the extreme stringency of the criteria, which demanded directional consistency across continents, strict statistical thresholds for gene-editing lethality, and bidirectional alignment between population genetics and lab data. Nevertheless, the swarm updated three hypotheses. The absence of findings across the broader 157-entity landscape suggests that unstratified, pan-cancer genetic scans are too noisy for these questions, and indicates that the current focused, subtype-specific approach is the more rigorous path forward. This warrants further investigation through the narrowed lens now in place.\n\nThe open questions now are whether liver- and colon-derived *LDLR* expression signals truly colocalize with CRC risk in an ancestry- and subtype-specific manner, and whether *PTGS2*’s causal effect is genuinely moderated by stromal infiltration in MSS tumors. The DepMap synthetic lethality screen remains especially promising: if *PTGS2* loss proves selectively lethal in *APC*-mutant, chromosomally unstable lines while sparing MSI models, it would forge a rare bridge from population-level genetics to a druggable, subtype-specific vulnerability. Next, the mission will stress-test these three integrated analyses with the full statistical machinery now aimed at this narrowed target set.\n\nThese findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 3
}